Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease

351Citations
Citations of this article
283Readers
Mendeley users who have this article in their library.

Abstract

IL (interleukin)-6 is a pivotal cytokine of innate immunity, which enacts a broad set of physiological functions traditionally associated with host defense, immune cell regulation, proliferation, and differentiation. Following recognition of innate immune pathways leading from the NLRP3 (NOD-, LRR-, and pyrin domain-containing protein 3) inflammasome to IL-1 to IL-6 and on to the hepatically derived clinical biomarker CRP (C-reactive protein), an expanding literature has led to understanding of the proatherogenic role for IL-6 in cardiovascular disease and thus the potential for IL-6 inhibition as a novel method for vascular protection. In this review, we provide an overview of the mechanisms by which IL-6 signaling occurs and how that impacts upon pharmacological inhibition; describe murine models of IL-6 and atherogenesis; summarize human epidemiological data outlining the utility of IL-6 as a biomarker of vascular risk; outline genetic data suggesting a causal role for IL-6 in systemic atherothrombosis and aneurysm formation; and then detail the potential role of IL-6 inhibition in stable coronary disease, acute coronary syndromes, heart failure, and the atherothrombotic complications associated with chronic kidney disease and end-stage renal failure. Finally, we review anti-inflammatory and antithrombotic findings for ziltivekimab, a novel IL-6 ligand inhibitor being developed specifically for use in atherosclerotic disease and poised to be tested formally in a large-scale cardiovascular outcomes trial focused on individuals with chronic kidney disease and elevated levels of CRP, a population at high residual atherothrombotic risk, high residual inflammatory risk, and considerable unmet clinical need.

References Powered by Scopus

Antiinflammatory therapy with canakinumab for atherosclerotic disease

6745Citations
N/AReaders
Get full text

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women

5293Citations
N/AReaders
Get full text

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

5077Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials

264Citations
N/AReaders
Get full text

The role of IL-6/JAK2/STAT3 signaling pathway in cancers

174Citations
N/AReaders
Get full text

Targeting the NLRP3 inflammasome in cardiovascular diseases

173Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Ridker, P. M., & Rane, M. (2021, May 28). Interleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease. Circulation Research. Lippincott Williams and Wilkins. https://doi.org/10.1161/CIRCRESAHA.121.319077

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 65

65%

Researcher 24

24%

Professor / Associate Prof. 7

7%

Lecturer / Post doc 4

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 60

62%

Biochemistry, Genetics and Molecular Bi... 22

23%

Agricultural and Biological Sciences 8

8%

Pharmacology, Toxicology and Pharmaceut... 7

7%

Article Metrics

Tooltip
Mentions
News Mentions: 2

Save time finding and organizing research with Mendeley

Sign up for free